Feb 04, 2026
Stokes Peebles, MD, right, Mark Rusznak, PhD, and their colleagues have identified a potential drug target for treating asthma.

Vanderbilt researchers, Drs. Stokes Peebles (Allergy, Pulmonary and Critical Care Medicine), Mark Rusznak and colleagues, have identified free fatty acid receptor 3 (FFAR3), a cell membrane receptor that can “reprogram” inflammatory immune cells, as a potential drug target for treating asthma.